These trials have enriched the therapeutic landscape for T2D patients, offering a range of GLP-1 receptor agonists with varying cardiovascular profiles, thus allowing clinicians to personalize treatment for each patient
23, NP4: Fig
Roque 2015)
Qin T, Hu Z, Zhang L, Lu F, Xiao R, Liu Y, et al
For type 2 diabetes managed with non-insulin medicines: People taking oral hypoglycaemic agents such as metformin, sulfonylureas, DPP-4 inhibitors, or SGLT2 inhibitors , or injectable medicines such as GLP-1 receptor agonists (for example, semaglutide or dulaglutide), can generally donate blood provided their diabetes remains well-controlled and they have no diabetes-related complications
Antibody details are listed in Supplementary Table 2